NEW YORK (360Dx) – Swedish diagnostic developer Immunovia today announced it has received a SEK4.9 million ($585,000) follow-on grant to support development studies for its Immray PanCan-d blood-based test for the early detection of pancreatic cancer.

The grant is from the Swelife Accelerator Innovation Program, which is designed to support Sweden's small-to-medium-sized enterprises. The Create Health Translational Cancer Center at Lund University will collaborate with Immunovia on its studies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.